Yard Force Robotic Mowers Have Obtained "Green Product" Mark by TÜV
31.1.2023 14:20:00 EET | Business Wire | Press release
Yard Force, a leading manufacturer of innovative outdoor power equipment, has announced the launch of its MB400 and MB800 robotic mowers on the German market. These models come equipped with Bluetooth and app control, providing users with convenient and easy access to their mowers from their smartphones or tablets.
In addition to their advanced technology features, both the Yard Force MB400 and MB800 come with a unique feature that allows for decking to be cleaned using water. This innovative feature not only makes cleaning the decking easier, but also helps to prevent the build-up of algae and other contaminants that can affect the appearance and longevity of the decking.
The Yard Force MB400 and MB800 are also equipped with a free garage, providing users with a convenient and secure storage solution for their mowers. This is particularly useful for those who wish the robotic mower could find shelter during rain or snow and use the robotic mower for a longer life.
Yard Force launches the two new models on the 10th anniversary of its robotic mowers, setting the standard once again:
In addition to their impressive features, both the Yard Force MB400 and MB800 have been awarded the "Green Product" certification by TÜV, a leading certification organizaition for environmental, social, and governance (ESG) standards. This certification recognizes the mowers' eco-friendly design and technology, making them a smart and sustainable choice for homeowners looking to reduce their carbon footprint.
In 2013, the company started selling its robotic mowers in Germany and has since equipped tens of thousands of German gardens with the innovative and practical robotic mowers.
The new Yard Force MB400 and MB800 are designed to provide users with a convenient and efficient solution for maintaining their lawns. With maximum 400m2 and 800 m2 working area respectively, these mowers are perfect for small to medium sized lawns, and can easily navigate around obstacles such as trees and garden furniture.
The Bluetooth and app control features of the Yard Force MB400 and MB800 allow users to easily set up and customize their mowing schedule, as well as monitor the mower's performance and receive notifications on their smartphone or tablet. This level of control and convenience makes the MB400 and MB800 a popular choice for busy homeowners who want to maintain their lawns without the hassle of traditional mowing methods.
The decking cleaning feature of the Yard Force MB400 and MB800 is another standout feature that sets these mowers apart from their competitors. By using water to clean the decking, users can easily remove dirt and debris, ensuring that their decking stays looking clean and fresh all year round. This feature also helps to prevent the build-up of algae and other contaminants, which can damage the decking and reduce its lifespan.
Overall, the Yard Force MB400 and MB800 are a highly innovative and convenient solution for maintaining a healthy and well-groomed lawn. With their advanced technology, eco-friendly design, and unique decking cleaning feature, these mowers are sure to be a hit with German homeowners looking for a more efficient and sustainable way to care for their lawns.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005560/en/
Contact information
Email: linyinlu@sumec.com.cn
Phone number: +86-13770517766
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
